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Abstract. A randomized trial was carried out from 1991 to 1993 among women attending an antenatal clinic in 
Ebolowa, Cameroon where malaria is hyperendemic and transmission occurs at a high level all year round. All 
pregnant women attending the clinic for their first prenatal visit between October 1991 and November 1992 were 
alternately assigned to chloroquine (CQ) or control (CT) groups. Chloroquine was given under observation at a weekly 
oral dose of 300 mg. At delivery, smears from maternal, cord, and placental blood were made and stained with 
Giemsa for parasites. An in vivo chloroquine sensitivity investigation was carried out on women attending the post- 
natal consultation to evaluate the level of chloroquine resistance in the target population. The efficacy of chloroquine 
was moderate in placental infection (39.2% infected in the CQ group versus 57.8% in the CT group: P = O.OS), 
probably because of a resistance to chloroquine estimated to be 10.9%. In the CQ group, the mean birth weight was 
significantly higher ( P  = 0.02) and the proportion of low birth weight newborns was lower (10.5% versus 27.7%; P 
= 0.02). A strong correlation between placental infection and birth weight was observed: the mean birth weight 
difference between infected and noninfected placentae was 359 g ( P  < 0.0001) and the proportion of low birth weight 
new born babies was 35.6% versus 5.9% ( P  = 0.0001). In Cameroon, in spite of a moderate resistance to chloroquine, 
this drug proved to be highly effective in increasing birth weight when administered to primigravidae. We therefore 
think such a prophylaxis should be recommended only to primigravidae in high transmission areas. 
In areas of high endemicity, malaria during pregnancy can 
induce such harmful effects as maternal anemia and low 
birth weight in newboms.14 Although the World Health Or- 
ganization has responded by recommending malaria che- 
moprophylaxis during pregnancy: recent studies show that 
application to all women irrespective of their parity could 
have disappointing results.6, One alternative might be to re- 
strict chemoprophylaxis solely to primigravidae, the group 
most vulnerable to malaria8.9 and the delivery of low birth 
weight babies (Kortmann HF, 1972, Malaria and Pregnancy. 
M.D. Thesis, Drukkerij Elinkwijk, Utrecht, The Nether- 
lands).*. lo However, the increase of Plasmodiurn fakiparum 
resistance to chloroquine could reduce the efficacy of this 
inexpensive and well-tolerated drug. Other drugs such as 
dapsone-pyrimethamine7 or mefloquine4 may be considered 
for use, but they are expensive and have greater side effects. 
Prophylaxis with either chloroquine or amodiaquine is 
generally recommended in Cameroonian antenatal clinics; 
however, compliance among pregnant women is poor. To 
investigate the effects of regular chloroquine administration 
on primigravidae in an area where there is moderate resis- 
tance to the drug, we conducted a controlled chemoprophy- 
laxis trial in a semirural region of Cameroon. 
SUBJECTS AND METHODS 
Subjects. The study lasted from October 1991 to April 
1993 and was carried out on pregnant women attending the 
antenatal clinic at Enongal Hospital in Ebolowa, Cameroon. 
The town of Ebolowa, with a population of 35,000, is situ: 
ated 160 km south of Yaounde. Pregnant women taking part 
in the study had to be living either in the town or within a 
25-km radius of its cente ' This peripheral zone consists of I 1 7 
small villages set in the midst of traditionally farmed cocoa 
plantations, the region's prime source of income. While the 
Boulou are the main ethnic group, the town is inhabited by 
a large colony of Bamileke, whose members originate from 
the westem part of the country and are usually involved in 
business and commerce. The region is dominated by tropical 
rain forests and malaria here is hyperendemic, with a high 
rate of transmission occurring all year round. 
After being examined by the hospital physician, any pri- 
migravida living in the study area and attending the clinic 
for a first prenatal visit between October 1991 and Novem- 
ber 1992 was introduced to an investigator who obtained 
their informed consent and allocated them alternately to a 
chloroquine treatment (CQ) group or a control (CT) group. 
Each woman's age, ethnicity, residence, and socioeconomic 
status (Table 1) was recorded. ' 
Women belonging to the CQ group received one 300-mg 
oral dose of chloroquine (Nivaquine Forte@; Rhone Poulenc 
Sante Laboratory, Antony, France) per week under obser- 
vation from the first visit until delivery. Women in the CT 
group, on the other hand, followed the usual hospital pro- 
cedures; placebos were not used l )  incase anyone eventually 
contracting malaria rejected proper treatment in the false be- 
lief that they were already being treated, and 2) because of 
technical difficulties of reproducing the exact amount of the 
chloroquine tablets. 
Once a week, each of the women was visited at home by 
an investigator, asked about febrile episodes and drug intake 
between visits, and had her axillary temperature taken. Thick 
blood smears were made once every two weeks in the ab- 
sence of febrile episodes, or at the time of the visit when a 
temperature exceeded 38°C. If a CQ group woman showed 
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TABLE 1 
CharacteriSliCS of treated and control subjects on entry into the study 
Treated Controls 
characteristics No. (‘%I No. (Cl 
Age (years) 
515 13 
15.1-17 38 
17.1-19 41 
19.1-21 23 
21.1-23 7 
>23 9 
Low 11 
Medium 50 
Socioeconomic status“ 
High 39 
District 
Central 98 
q,eripheral 33 
Ethnic group 
Boulou 69 
Bamileke 27 
Mbam 10 
Other 25 
(9.9) 
(29) 
(31.3) 
(17.6) 
(5.3) 
(6.9) 
(11) 
(39) 
(74.8) 
(25.2) 
(52.7) 
(20.6) 
(19) 
(50) 
(7.6) 
14 (10.4) 
45 (33.3) 
40 (29.6) 
20 (14.8) 
12 (8.9) 
4 (3) 
22 (1 9.3) 
35 (30.7) 
57 (50) 
96 (71.1) 
39 (28.9) 
82 (60.7) 
21 (15.6) 
22 ( 16.3) 
10 (7.4) 
* Study subjects interviewed by investigators were given scores according 10 the follow- 
ing criteria: dwellings: floors, concrete (1 point) or mud (O points); walls, concrete (1) or 
mud (O); roofs, corrugated iron (1) or thatched (O); domestic equipment: ( I  point if posi- 
tive): refrigerator, radio, television. automobile, motorbike. According Io their scores, the 
socioeconomic status was then categorized as low (1-2 points). medium (3-5 points). or 
high (6-8 points). 
signs of having had a suspected attack of malaria, defined 
as an association of hyperthermia and parasitemia, or as an 
isolated parasitemia of more than 5,000 parasites per mi- 
croliter of blood, this was taken to mean that chloroquine 
treatment was failing, and such cases were treated with oral 
quinine. Women in the CT group showing similar signs were 
administered a therapeutic dose of chloroquine (25 mgkg of 
body weight) and, if this had no effect, oral quinine (10 mg/ 
kg, three times a day for seven days). 
The protocol was examined and officially approved by the 
Comite National d’Ethique (Paris, France) and the Comite 
d’Ethique (Ministere de la Sante du Cameroun). 
Investigators recorded outcomes of pregnancies and de- 
tailed information on newborns (clinical status and birth 
weight) at the time of delivery at the Enongal Hospital ma- 
ternity ward. Maternal, cord, and placental blood samples 
were also taken and examined for parasites. 
Approximately halfway through the study, positive cases 
of P. faleiparuin infection among all postnatal clinic outpa- 
tients who had delivered at Enongal were identified by 
means of fingerprick blood smears. They were then treated 
with chloroquine and underwent in vivo testing to investi- 
gate parasite sensitivity to the drug. The parasitemia was 
checked seven days later according to an adult application 
of the protocol described by Breman and others.” 
Laboratory methods. Thick blood smears were stained 
with Giemsa and 100 oil-immersion microscopic fields were 
examined for malaria parasites. Parasites and white blood 
cells were enumerated, and parasite density was calculated 
according to an assumed average of 8,000 leukocytes/mm3. 
Statistical methods. Data were analyzed with BMDP sta- 
tistical software (BMDP Statistical Software, Inc., Los An- 
geles, CA). The chi-square test was used to test differences 
in proportions and analysis of variance was used to test dif- 
ferences in means. Relative risk (RR) confidence limits were 
calculated according to the formula of Greenland and Rob- 
ins.I2 Multiple linear regression and logistic regression were 
used to test the effect of chloroquine intake and other cov- 
ariates on birth weight. 
RESULTS 
Study population. Two hundred sixty-six women were 
enrolled in the study. One hundred thirty-one of them in the 
CQ group had weekly prophylaxis administered by the in- 
vestigators, while the other 135 (CT group) women, know- 
ing that they would be treated with chloroquine or quinine 
at the first sign of infection, consented to receiving no ther- 
apy. The CQ and CT groups were compared on the basis of 
age, ethnicity, residence, and socioeconomic status. Table I 
shows that on entering the study, no difference between the 
two groups was recorded for any of these variables. 
For personal reasons entirely unrelated to the trial, three 
women withdrew from the CQ group and four left the CT 
group shortly after enrollment, and we lost contact with 14 
CQ and 10 CT group subjects during follow-up. Eleven 
women from the CQ group and 15 from the CT group had 
just settled in Ebolowa; they had normal follow-up at the 
beginning before returning to their home provinces a few 
weeks prior to delivery. 
One hundred three women from the CQ group and 106 
from the CT group remained in the study area and were 
followed for the duration of their pregnancies. Twenty-three 
and 17, respectively, delivered in their home villages, so our 
investigators were unable to measure the birth weight of 
their newborns. The same was true of the 16 CQ-treated and 
19 control subjects who went into the maternity wards of 
the Province Hospital. One CQ-treated subject delivered be- 
fore the first investigator visit and was thus not administered 
any chloroquine. Having consequently had neither prophy- 
laxis nor follow-up, this woman was excluded from the final 
analysis. In the end, we were reduced to analyzing the 63 
CQ group and 70 CT group women who lasted the course 
and whose babies were eventually delivered and weighed at 
Enongal Hospital. 
No differences were found with regard to residence, du- 
ration of follow-up, and socioeconomic status when the two 
groups were compared at delivery (Table 2), although the 
CT group women appeared to be younger (x2 = 13.37; de- 
grees of freedom [dfl = 5; P = 0.02) and proportionally 
more of them were ethnic Boulous than Bamilekes (x2 = 
11.44; df = 4; P = 0.02). 
Compliance with chemoprophylaxis and resistance to 
chloroquine. By the time of delivery, the 63 CQ women 
had been administered an average total of 2,500 mg of chlo- 
roquine (i.e., 8.3 weekly intakes during follow-up). 
Of the CT group women, 39 (56%) declared that on their 
own initiative, they had taken one or more short (generally 
infratherapeutic) treatments of either chloroquine or amodia- 
quine during the course of their pregnancy because they 
thought they had contracted malaria. The investigators treat- 
ed an additional 19 CT group women for suspected malaria 
attacks with chloroquine (25 mgkg over a three-day period) 
and then, in the case of treament failure, oral quinine (10 
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TABLE 2
Characteristics of treated and control subjects at delivery 
TABLE 4 
Mean birth weight (in grams) in relation to treatment status 
Treated Controls 
Characteristics No. (%) No. (%I 
~~ 
Age (years) 
515 2 (3.2) 
15.1-1 7 15 (23.8) 
17.1-19 19. (30.2) 
19.1-2 1 15 (23.8) 
21.1-23 5 (7.9) 
>23 7 (11.1) 
Low 4 (7.5) 
Medium 24 (45.3) 
High 25 (47.2) 
Socioeconomic status" 
District 
Central 47 (74.6) 
Peripheral 16 (25.4) 
Boulou 28 (44.4) 
Mbam 7 (11.1) 
Ethnic group 
Bamileke 18 (28.6) 
Other 10 (15.8) 
Duration of follow-up (months) 
52 13 (20.6) 
2.1-3 8 (12.7) 
3.1-4 15 (23.8) 
4.1-5 10 (15.9) 
>5 17 (27.0) 
8 
26 
13 
10 
II 
2 
10 
31 
19 
47 
23 
50 
7 
5 
8 
17 
15 
17 
13 
8 
(11.4) 
(37.1) 
(1 8.6) 
( 14.3) 
(15.7) 
(2.9) 
(1 6.6) 
(5 1.7) 
(3 1.7) 
(67. I )  
(32.9) 
(7 1.4) 
(1 0.0) 
(7. I ) 
(1 1.4) 
(24.3) 
(2 1.4) 
(24.3) 
(1 8.6) 
(11.4) 
* For additional information, see Table I .  
mgkg, three times a day for seven days). Four women were 
found to be vomiting and were thus admitted to the hospital 
for parenteral quinine treatment. Of the CQ group women, 
seven showed signs of malaria attacks and were treated with 
above-mentioned dose of oral quinine. Five were admitted 
to the hospital for parenteral treatment. 
The in vivo chloroquine sensitivity investigation showed 
that 10.9% (95% confidence interval [CI] = 1.9-19.9%) of 
the 46 parasitemic women attending postnatal clinic consul- 
tations still had positive smears seven days after chloroquine 
treatment (25 mgkg of body weight). 
Effect of prophylaxis on placental infection. One hun- 
dred twenty placental smears were collected and examined. 
Thirty-seven (57.8%) from 64 CT group women were found 
positive, as were 22 (39.3%) from 56 CQ subjects (x2 = 4.1; 
df = 1; P = 0.043; Table 3), showing a 32% protective 
efficacy of regular chloroquine prophylaxis. 
Effect of prophylaxis on birth weight. There were two 
spontaneous abortions in the CT group, four babies were 
stillborn (two in each group), and five were delivered by 
Caesarean section (two in the CT group and three in the CQ 
TABLE 3
Proportion of infected placentae by inclusion status 
Treated Controls 
No. (C) No. (%) RR* 
Infected placenta 22 (39.3) 37 (57.8) 0.68 (0.46-0.99) 
Uninfected placenta 34 (60.7) 27 (42.2) 
* RR = relative risk. Numbers in parentheses indicate 95% confidence limits. x' = 4.10. 
degrees of freedom = 1, P = 0.043. 
._ 
Treated Controls Difference* 
Mean value 3,069.8 2,862.3 207.5 
Number of subjects 57 65 
SEM? 56.8 68.0 (33.8-381.6) 
* Numbers in parentheses indicate 95% confidence limits. I-test value = 2.3, degrees of 
f SEM = slandard error of the mean. 
freedom = 121. P = 0.02. 
group) and their weights were not recorded. The mean birth 
weight of the 122 remaining babies in the two groups was 
compared. It was significantly higher in the CQ group than 
in the CT group (a difference of 207 g; P = 0.02; Table 4). 
The relative risk of low birth weight (< 2,500 g) in a new- 
born was also significantly reduced by prophylaxis (RR = 
0.38, 95% CI = 0.16-0.89, x2 = 5.66, P = 0.02; Table 5). 
There was no birth weight more than 4,000 g in the CQ 
group and only one (4,550 g) in the CT group. 
Age and ethnicity distribution in the two Enongal groups 
changed between enrollment and delivery (Table 2). Age 
was higher in the CQ group, and this variable (but not eth- 
nicity) was correlated with placental infection, with older 
women having fewer placental infections x2 = 16.62; df = 
5; P = 0.03). We performed multiple regression to assess 
the relationship between chloroquine intake and birth 
weight, taking all covariates into account. Neither age nor 
other covariates significantly influenced birth weight; after 
adjustment for all variables, the difference between the two 
groups was 230.2 g (Table 6). Logistic regression on low 
birth weight showed similar results (Table 7) (odds ratio for 
having a low birth weight given that the mother belongs to 
the CQ group = 0.30, 95% CI = 0.05.-0.78, no effect of 
other covariates) 
Relationship between placental infection and birth 
weight. Mean birth weights were much higher when placen- 
tas were not infected (difference of 358 g; P < Table 
8), and placental infection increased the relative risk of a 
newborn with a low birth weight (RR = 7.24, 95% CI = 
2.28-22.98, xz = 17.64. df = 1; P < Table 9). 
DISCUSSION 
An earlier study conducted in Burkina Faso, an area of 
high endemicity with marked seasonal variations, showed 
that despite being very effective in preventing placental in- 
fection, administering chloroquine prophylaxis to all preg- 
nant women in general had little effect on the mean birth 
TABLE 5
Proportion of low birth weights (less than 2,500 g) by treatment 
status 
Treated Controls 
-~ 
No. (%) No. (70) RR* 
Birth weight <2,500 g 6 (10.5) 18 (27.7) 0.38 
Birth weight 22,500 g t  51 (89.5) 47 (72.3) 
degrecs of freedom = 1, P = 0.0 I I. 
(O. 16-0.89) 
* RR = relative risk. Numbers in pnrentheses indicate 95% confidence limits. x2 = 5.66, 
t Only one birth weight w a ~  greater than 4,000 g in the control group (none in the treated 
group). 
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TABLE 6 
Multiple linear regression on birth weight, accounting for treatment 
status, socioeconomic status, duration of follow-up, district, and 
age 
Variable Coefficient F* 
Constant 2,590.7 
Inclusion status 230.2 5.10 
Socioeconomic status -30.5 0.97 (NS) 
Duration of follow-up 1.2 0.95 (NS) 
District 3.4 0.94 (NS) 
Age 13.3 0.56 INS) 
* NS = not significant. 
weight of their babies.6 Analysis of the primigravidae subset 
showed a higher, although not statistically significant, dif- 
ference in birth weights between the treated and control 
groups than was the case in the population as a whole. One 
explanation for these results was that as far as birth weight 
was concerned, chloroquine had no noticeable effect among 
multigravidae, while primigravidae, a known high-risk group 
for malaria and low birth weight, were the only ones bene- 
fiting from prophylaxis. Similarly to our findings in Burkina 
Faso, literature on the subject shows that three other che- 
moprophylaxis trials7* I3. l4 were unable to prove an overall 
effect on birth weight, yet noted a trend towards an increase, 
albeit not statistically significant, in birth weights among the 
offspring of primigravidae. In one of these studies: Green- 
wood and others demonstrated a significant difference in the 
subset of primigravidae taking prophylaxis for more than six 
weeks. Only one trial has provided evidence of a probable 
overall increase in birth weights between treated and control 
groups among all pregnant women in general.15 
Since placental malaria prevalence was moderate in Bur- 
kina Faso (19% in the control group), we decided to conduct 
another study in a region where transmission was higher to 
accurately evaluate the efficacy of chloroquine prophylaxis 
when restricted to primigravidae. 
Our results in Cameroon establish that regular, supervised 
chloroquine administration is effective in primigravidae and, 
for the first time among this subset of females, a highly 
significant 207-g difference in mean birth weights was ob- 
served between the treated and control groups. The propor- 
tion of babies with low and very low birth weights was 
greatly reduced, and there was no obvious increase in high 
TABLE 7
Logistic regression on low birth weight, accounting for treatment 
status, duration of follow-up, ethnicity, district, age, and socio- 
economic status" 
Exponential 
(cocl'ficientj 
Variable [OR) OR95WCI Pt  
~~ 
Inclusion status 0.20 (0.05-0.78) 0.0 1 
Duration of follow-up - - 0.57 (NS) 
Ethnicity - - 0.71 (NS) 
District - - 0.72 (NS) 
Age - - 0.75 (NS) 
Socioeconomic status - - 0.79 (NS) 
Constant - - <10-4 
* OR = odds ratio: CI = confidence interval. Values of the OR are not given since this 
varhble is not binary-coded and cannot be calculated fro111 the exponential values of the 
coefficient. 
t NS = not significanl. 
TABLE 8 
Mean birth weight (in grams) in relation to placental infection 
Infected Uninfccled 
placenta placcnta Difference* 
Mean value 2,766.6 3,125.2 358.6 
Number of subjects 59 61 
SEM? 65.6 55.6 (190-527.1) 
* Numbers in parentheses indicate 9 5 1  confidence limits. r-test value = 4.18, degrees of 
freedom = 119. P < 0.0001, 
birth weight newborns. Gamer and otherst6* l 7 feared that in- 
terventions leading to an increase in mean birth weight could 
paradoxically result in higher perinatal mortality due to a 
higher risk of obstructed labor. Our data and the recent work 
of Greenwood and otherst8 does not confirm this hypothesis. 
When we began the study, we decided to follow-up 250 
women during their pregnancy to end up with 200 subjects 
(100 in each group) at delivery. This was thought to be a 
sufficiently sized sample for detecting the least possible ef- 
fect of prophylaxis on birth weight. Unfortunately, however, 
follow-up contact was lost with an unexpectedly high num- 
ber of women between enrollment and delivery and the trial 
time limits did not allow for replacements. The most likely 
reason for so many losses was the severe economic crisis 
that hit Cameroon during that period. The majority of the 
population in Ebolowa is economically dependent on the co- 
coa trade. As raw material prices continued to decrease, 
women were unable to afford to deliver at Enongal Hospital 
and preferred either to stay home or to go to the Province 
Hospital where lower fees were charged. There were no oth- 
er obvious reasons for not giving birth at Enongal because 
the hospital's reputation remained at a consistently high level 
throughout the period of the study. In the end, the CQ and 
CT groups both lost an almost equal number of subjects (67 
and 65, respectively). 
The intervention groups changed in composition between 
enrollment and the end of the study. At the beginning, both 
groups were similar for all variables; at delivery, however, 
there were more Bamileke and fewer Boulou in the CQ 
group and, on average, women were older than in the CT 
group. Neither of these two variables (age and ethnicity) was 
related to birth weight and age was the only one that could 
be linked to placental infection. We performed a regression 
analysis and a logistic regression eliminating the influence 
of all other variables and confirming that the onIy relevant 
factor for an increase in birth weight was prophylaxis intake. 
We had previously used chloroquine in Burkina Faso 
where at the time of the trial, there was, if anything, a neg- 
ligible rate of resistance to the drug. In Ebolowa, our find- 
TABLE 9 
Proportion of low birth weights (less than 2,500 g) by placental 
infection 
Infected Uninfectcd 
placenva placenta 
No. (7oj No. [%) RR* 
Birth weight <2,500 g 21 (35.6) 3 (4.9) 7.24 
(2.28-22.98) 
Birth weight 22,500 g 38 (64.4) 58 (95.1) 
* RR relative ri&. Numbers in parcntheses indicale 95% confidence limits. x' = 17.64. 
degrees of freedom = I ,  P < 0,0001. 
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ings showed a 10% resistance to chloroquine, and one might 
have thought that a more effective drug could have been 
chosen. As stressed by Nahlen and others,lg “the strategy for 
diminishing the impact of malaria in pregnancy needs effec- 
tive and safe drugs for treatment and chemoprophylaxis, an 
efficient system for delivering the drugs, and acceptance of 
drugs by pregnant women”. Only a few drugs are actually 
safe for use during pregnancy. Although pyrimethamine may 
be a long-used and well-accepted treatment, apart from rare- 
ly reported accidents such as agranulocytosis or a teratogenic 
effect observed on rats but never proven in humans,’ the 
degree of resistance to this drug makes it less effective than 
chloroquine in areas where transmission is high.lg Proguanil 
alone or in association with chloroquine is safe but must 
taken daily, which raises questions about the compliance of 
such a regimen in public health policies. Mefloquine has not 
yet been established as safe4.‘’ and its price is still too high 
to be offered to African women in systematic chemoprophy- 
laxis. 
Thus, chloroquine remains one of the best prophylactic 
drugs for areas of hyperendemicity. It is inexpensive, well- 
accepted, and well-tolerated (especially in its 300-mg coated 
form that allows for a single weekly administration). It has 
proved to  be highly effective in increasing birth weight in 
the newborns of primigravidae. While restricting it to this 
group of women can improve the feasibility of health poli- 
cies aimed at preventing malaria during pregnancy, the most 
serious problem remains actually getting them to comply 
without supervision.20- 21 
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